67104-97-6

Usage

Uses

Used in Pharmaceutical Applications:
2-METHYL-[1,2,5]THIADIAZOLIDINE 1,1-DIOXIDE is used as a building block in the synthesis of various pharmaceutical drugs due to its unique chemical properties and potential therapeutic effects.
Used in Agricultural Applications:
In the agricultural industry, 2-METHYL-[1,2,5]THIADIAZOLIDINE 1,1-DIOXIDE is utilized for its antimicrobial and antiviral properties, making it a potential candidate for the development of new agrochemicals to combat pests and diseases.
Used in Drug Development:
2-METHYL-[1,2,5]THIADIAZOLIDINE 1,1-DIOXIDE is employed in drug development for its potential to contribute to the creation of new therapeutic agents, particularly given its antimicrobial and antiviral properties, which are valuable in addressing current and emerging health challenges.

Upstream product

• 67104-93-2 2-tert-butyl-5-methyl-[1,2,5]thiadiazolidine 1,1-dioxide 
• 109-81-9 N-methyl-ethane-1,2-diamine 
• 7803-58-9 SULFAMIDE 
• 263719-77-3 tert-butyl 5-methyl-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide 
• 503310-74-5 5-methyl-1,1-dioxo-1λ⁶-[1,2,5]thiadiazolidine-2-carboxylic acid benzyl ester 

Downstream Products

• 144432-71-3 4-(1,1-dioxo-5-methyl-1,2,5-thiadiazolidin-2-yl)nitrobenzene 
• 144432-52-0 5-Methyl-2-(4-nitrobenzyl)-1,2,5-thiadiazolidine-1,1-dioxide 
• 1092980-88-5 C₉H₁₀FN₃O₄S 
• 1193318-27-2 (2S,4S)-2-[(5-methyl-1,1-dioxo-[1,2,5]thiadiazolidin-2-yl)carboynl]-4-tritylthio-1-(allyloxycarbonyl)pyrrolidine 
• 1237802-48-0 C₂₄H₂₅F₅N₂O₅S₂ 
• 1202923-74-7 3-benzyloxy-2-[5-(4-fluoro-benzyl)-thiazol-2-yl]-9-(5-methyl-1,1-dioxo-[1,2,5]thiadiazolidin-2-yl)-7-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one 
• 1254301-12-6 3-benzyloxy-7-bromo-9-(5-methyl-1,1-dioxo-[1,2,5]thiadiazolidin-2-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxylic acid methyl ester 
• 1221400-16-3 5-(5-methyl-1,1-dioxo-1λ6-[1,2,5]thiadiazolidin-2-yl)-isophthalic acid dimethyl ester 
• 936364-14-6 4-fluoro-2-(1,1-dioxo-5-methyl-1,2,5-thiazolidin-2-yl)benzonitrile 

Relevant academic research and scientific papers

7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones designed by a “cut and glue” strategy are dual aurora a/vegf-r kinase inhibitors

Although overexpression and hyperactivity of protein kinases are causative for a wide range of human cancers, protein kinase inhibitors currently approved as cancer drugs address only a limited number of these enzymes. To identify new chemotypes addressing alternative protein kinases, the basic structure of a known PLK1/VEGF-R2 inhibitor class was formally dissected and reassembled. The resulting 7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones were synthesized and proved to be dual inhibitors of Aurora A kinase and VEGF receptor kinases. Crystal structures of two representatives of the new chemotype in complex with Aurora A showed the ligand orientation in the ATP binding pocket and provided the basis for rational structural modifications. Congeners with attached sulfamide substituents retained Aurora A inhibitory activity. In vitro screening of two members of the new kinase inhibitor family against the cancer cell line panel of the National Cancer Institute (NCI) showed antiproliferative activity in the single-digit micromolar concentration range in the majority of the cell lines.

Discovery of New Imidazo[2,1- b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising in Vitro and in Vivo Anti-melanoma Activity

BRAF is an important component of MAPK cascade. Mutation of BRAF, in particular V600E, leads to hyperactivation of the MAPK pathway and uncontrolled cellular growth. Resistance to selective inhibitors of mutated BRAF is a major obstacle against treatment of many cancer types. In this work, a series of new (imidazo[2,1-b]thiazol-5-yl)pyrimidine derivatives possessing a terminal sulfonamide moiety were synthesized. Pan-RAF inhibitory effect of the new series was investigated, and structure-activity relationship is discussed. Antiproliferative activity of the target compounds was tested against the NCI-60 cell line panel. The most active compounds were further tested to obtain their IC50 values against cancer cells. Compound 27c with terminal open chain sulfonamide and 38a with a cyclic sulfamide moiety showed the highest activity in enzymatic and cellular assay, and both compounds were able to inhibit phosphorylation of MEK and ERK. Compound 38a was selected for testing its in vivo activity against melanoma. Cellular and animal activities are reported.

IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME

Provided is a pharmaceutical composition for preventing and treating tumors, the pharmaceutical composition including an imidazooxazole derivative compound, a solvate, a stereoisomer, or a pharmaceutically acceptable salt thereof as an active ingredient.

CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I); where A1, A2, G, R1, R2, R3, R4, and W are described herein.

AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described herein.

6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES

The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 and Q are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.

Carbazole-containing sulfonamides and sulfamides: Discovery of cryptochrome modulators as antidiabetic agents

A series of novel carbazole-containing sulfonamides and sulfamides were synthesized. A structure-activity relationship study of these compounds led to the identification of potent cryptochrome modulators. Based on the results of efficacy studies in diet-induced obese (DIO) mice, and the desired pharmacokinetic parameters, compound 41 was selected for further profiling.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)

Carbazole-Containing Sulfonamides as Cryptochrome Modulators

The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, F, G, H, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma.

Synthesis of new 6-(4-Fluorophenyl)-5-(2-substituted pyrimidin-4-yl) imidazo[2,1-b] thiazole derivatives and their antiproliferative activity against melanoma cell line

Synthesis of a new series of pyrimidinyl-imidazo[2,1-b]thiazole derivatives is described. Their antiproliferative activity against A375 human melanoma cell line was tested and the effect of substituents on the pyrimidinyl ring side chain was investigated.